Table 3.

Changes in PD-related parameters at 3 and 6 months after tocilizumab.

Parameter	Baseline	3 Months (V1)	6 Months (V2)	p-Value
GI	0.98 ± 0.12	0.85 ± 0.17	0.81 ± 0.18	* <0.05; ** NS
% sites with plaque	32.4 ± 16.9	30.5 ± 14.2	30.2 ± 15.8	* NS; ** NS
% sites with BOP	10.2 ± 8.6	7.3 ± 6.1	6.5 ± 6.8	* <0.05; ** NS
PPD (mm)	2.8 ± 0.4	2.1 ± 0.12	2.1 ± 0.09	* <0.05; ** NS
% sites with PPD ≥ 4 mm	12.7 ± 2.5	7.8 ± 3.9	6.1 ± 3.6	* <0.05; ** NS
CAL (mm)	3.5 ± 1.2	2.58 ± 0.30	2.55 ± 0.31	* <0.05; ** NS
% sites with CAL ≥ 4 mm	12.5 ± 0.2	11.2 ± 0.4	11.3 ± 0.9	* <0.05; ** NS

GI, gingival index; BOP, bleeding on probing; PPD, probing pocket depth; CAL, clinical attachment loss; * V1 compared to baseline; ** V2 compared to V1; p > 0.05 non-significant (NS); V1 and V2, visit 1 and 2, respectively.